The Efficacy and Safety of DA-3030 (Recombinant Human Granulocyte Colony-Stimulating Factor) in Neutropenia after the Remission Induction Chemotherapy in Patients with Acute Myelogenous Leukemia

• Published in: Cancer research and treatment Vol. 35; no. 1; pp. 66 - 68
• Main Authors: Min, Young Joo, Suh, Cheol Won, Park, Keon Uk, Yoon, Sung Soo, Park, Chan Hyung, Lee, Hong Ghi
• Format: Journal Article
• Language: English
• Published: Korea (South) 대한암학회 01.02.2003
• Subjects: 의약학; Acute myelogenous leukemia; rhG-CSF; Neutropenia
• ISSN: 1598-2998; 2005-9256
• DOI: 10.4143/crt.2003.35.1.66

This study was conducted to determine the efficacy and safety of DA-3030 (a recombinant methionyl human granulocyte colony-stimulating factor, rhG-CSF), after remission induction chemotherapy, in patients with acute myelogenous leukemia (AML). After the remission induction chemotherapy, with idarubicin (12 mg/m2/day for 3 days) and cytarabine (200 mg/m2/day for 7 days), 26 patients with newly diagnosed AML were assigned to receive DA-3030 (200mug/m2/day), starting 24 hours after the completion of the remission induction chemotherapy, until their neutrophil count recovered to greater than 1, 000/muL for 3 consecutive days. The median time from the initiation of the chemotherapy to the neutrophil recovery of 1, 000/muL was 21 days (range, 12~41). Treatment with DA-3030 was not associated with significant adverse side effects. The most frequently reported side effects were musculo-skeletal pain (13%) and headache (13%). The DA-3030 is a safe rhG-CSF for the treatment of neutropenia after remission induction chemotherapy in patients with AML.